Free Trial

Silk Road Medical Q2 2024 Earnings Report

Silk Road Medical EPS Results

Actual EPS
-$0.42
Consensus EPS
-$0.38
Beat/Miss
Missed by -$0.04
One Year Ago EPS
-$0.35

Silk Road Medical Revenue Results

Actual Revenue
$51.20 million
Expected Revenue
$49.74 million
Beat/Miss
Beat by +$1.46 million
YoY Revenue Growth
+13.00%

Silk Road Medical Announcement Details

Quarter
Q2 2024
Time
After Market Closes
Remove Ads

Silk Road Medical Earnings Headlines

Forget the chainsaw … Here’s DOGE’s next move
Donald Trump, Elon Musk and the Department of Government Efficiency have kept their word. Moving even faster than most people thought … Clearing out waste and inefficiency in our government.
See More Silk Road Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Silk Road Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silk Road Medical and other key companies, straight to your email.

About Silk Road Medical

Silk Road Medical (NASDAQ:SILK) operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.

View Silk Road Medical Profile

More Earnings Resources from MarketBeat